港股異動 | 京東健康(6618.HK)高開8.46% 2021年增長58.3% 調整後利潤增長91.5%
格隆匯3月29日丨京東健康(6618.HK)高開8.46%,報45.5港元,總市值1453億港元。該公司昨日盤後公佈業績,2021年總收入306.8億元,同比增長58.3%,其中服務收入增長72.7%;非國際財務報吿準則指標下(Non-IFRS)淨利潤達14.0億元,同比增長91.5%。截至2021年12月31日,京東健康的年度活躍用户數量達到1.23億,相比2020年活躍用户數淨增加3356萬。全國範圍內的藥品倉庫和非藥品倉庫數量分別增至19個和超過400個,80%的自營藥品訂單實現次日達;京東健康互聯網醫院日均諮詢量已超過19萬。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.